The once-daily tablet also brought about 4% placebo-adjusted weight loss in 13 weeks with no GI dropouts, per Ascletis. Obesity phase III data is expected in 2028.
Recap by typeshit. Full story at BioPharma APAC.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
The GI and obesity doctor points to about 25% weight loss in the 2,339-adult trial of people with obesity but no diabetes, and says that figure isn't the whole story.
Reuters reported the approval as Novo shares sit down 13% this year. STEP Young data in kids aged 6 to 11 is due at ObesityWeek in November.
Loading…